-
![Team of professionals-GettyImages-511917982]( "Minimizing The Impact Of Human Errors Using Relational Risk Analysis")
Minimizing The Impact Of Human Errors Using Relational Risk AnalysisThis article describes how a mechanism-based risk analysis approach can provide two complementary opportunities for minimizing the likelihood of a human error impacting pharmaceutical and medical device risks.
-
![HPLC Vials-GettyImages-90658964]( "The Building Blocks Of A Robust Analytical Assay")
The Building Blocks Of A Robust Analytical AssayAnalytical assays aren't just important for quality control. Regulators expect them. These tips will help if you're just starting to build your analytical package.
-
![workers in lab wearing protective gear-GettyImages-1417392226]( "Environmental Monitoring Performance Qualification In New Drug Manufacturing Facilities")
Environmental Monitoring Performance Qualification In New Drug Manufacturing FacilitiesIn setting up a new manufacturing facility, a robust process for environmental monitoring must be established and cleanrooms in the classified areas must be properly qualified. Here are critical considerations to keep in mind.
-
![GettyImages-2182054861-mab-process-capture-3d-close-up]( "Balancing Protein A Resin Cost, Performance, And Productivity")
Balancing Protein A Resin Cost, Performance, And ProductivityOptimizing input parameters like DBC, flow rate, and resin durability is key to boosting productivity in downstream bioprocessing. Discover how to tailor resin choices to meet your specific process requirements.
-
![GettyImages-2217505892-AI-artificial-intelligence]( "AI Data Security: The 83% Compliance Gap Facing Pharmaceutical Companies")
AI Data Security: The 83% Compliance Gap Facing Pharmaceutical CompaniesA new study reveals a shocking truth: only 17% of pharmaceutical companies — including many CDMOs — have implemented automated controls to prevent sensitive data from leaking through AI tools.
-
![GettyImages-1213740865-robot-human-hand-AI]( "Here's What Limits AI's Outlook For Replacing Knowledge Workers")
Here's What Limits AI's Outlook For Replacing Knowledge WorkersEven after AI developers clean up hallucinations and other short-term issues, a large-scale workforce replacement faces a few intractable obstacles.
-
![GettyImages-1663374966-lab-microscope-mask-research-study]( "How Much Knowledge Work Can Biopharma Offload To AI? Answer: Not Much")
How Much Knowledge Work Can Biopharma Offload To AI? Answer: Not MuchIn biomanufacturing, knowledge work and manual work are deeply intertwined. One expert suggests replacing entire workflows with artificial intelligence seems unlikely.
-
![GettyImages-1403976499-scientist-pharma-manufacturing-vaccine]( "Non Animal Origin Squalene For High-Risk Applications")
Non Animal Origin Squalene For High-Risk ApplicationsExplore an ethical and sustainable alternative to shark-derived squalene that is backed by robust data to deliver identical performance in vaccine formulations without environmental compromise.
-
![ERP-GettyImage-1404810912]( "Pharma Enterprise Resource Planning: From Automation To AI-Driven Insights")
Pharma Enterprise Resource Planning: From Automation To AI-Driven InsightsPharmaceutical firms are increasingly turning to enterprise resource planning (ERP) systems to modernize operations. These platforms unify core functions, including supply chain management, manufacturing, and financial planning and analysis.
-
![Vial of Covid-19 Coronavirus Vaccine-GettyImages-1319914581]( "Managing Extractables And Leachables In HPAPI Manufacturing")
Managing Extractables And Leachables In HPAPI ManufacturingThese contaminants can compromise the quality, stability, and safety of a drug product, and regulatory bodies mandate assessment to protect patients.
-
![Hand With Key-GettyImages-186917322]( "Unlocking Value In Biopharma Operations: A C-Suite Call To Action")
Unlocking Value In Biopharma Operations: A C-Suite Call To ActionOperational readiness will separate the leaders from the laggards, whether you lead a pharma/biotech innovator, CDMO, or a combination of both.
-
![Document management systems-GettyImages-2085674337]( "Audit Trail Compliance And What To Look For In Mitigation Software")
Audit Trail Compliance And What To Look For In Mitigation SoftwareIn the pharma/biotech and medical device industries, the audit trail is important to have for accountability, data integrity, repeatability to create an event for investigation, and regulatory compliance.
-
![standing out from the crowd, individuality, special-GettyImages-1330022784]( "The New Clinical Packaging Paradigm: Differentiation And Decentralization")
The New Clinical Packaging Paradigm: Differentiation And DecentralizationThe rapid evolution toward flexible, decentralized clinical supply models is placing unprecedented strain on traditional clinical packaging organizations. Can traditional models adapt fast enough to stay viable?
-
![Validation-GettyImages-696525716]( "Process Validation: Optimizing Operational Excellence In Pharma And Medical Devices")
Process Validation: Optimizing Operational Excellence In Pharma And Medical DevicesProcess validation is often viewed as a costly regulatory formality. However, it is actually a strategic investment that, when integrated into business planning, delivers measurable outcomes in productivity, compliance, speed-to-market, and profitability.
-
![GettyImages-1076055404 chromatography, purification]( "Efficiently Select Your Antibody Or Antibody Variant Purification Strategy")
Efficiently Select Your Antibody Or Antibody Variant Purification StrategyExplore the evolution of antibody therapeutics from monoclonal antibodies to next-gen formats and discover innovative strategies for purifying these complex molecules in today’s landscape.
ABOUT BIOSIMILAR MANUFACTURING
Biosimilars are considered to be low-cost substitutions for pricy, large-molecule biologics. However, biosimilars must meet the same quality, safety, and efficacy as their reference biologic. Manufacturing biosimilars requires a more complicated procedure than that of manufacturing small molecule generics. Companies manufacturing biosimilars are focused on creating a chemical structure that is as close as possible to that of the reference product. Failure rates and operational costs pose a challenge for those companies involved in manufacturing biosimilars compared to those manufacturing small molecule generics.
Small molecule generics are created using the same active pharmaceutical ingredient (API) and, therefore, are chemically identical to that of the originator medicine. The manufacturing process for small molecules comprises only one-fifth of the total in-process tests required to meet Good Manufacturing Practice compared to that of biologic medicines (50 vs. 250 in-process tests). In fact, the manufacturing process for a large molecule is so complex, it cannot be duplicated by two different manufacturers, as the cells used in biologic medicines are unique to the company manufacturing each biologic.
Manufacturing a biologic consists of genetically modifying a cell, which becomes the basis for a cell line used for the production of the necessary protein for the biologic medicine. The protein is then separated from the cells and purified. Biosimilars are created from small alterations to the manufacturing process which creates a molecule that is not identical but closely resembles the reference product. While the differences in the biosimilar molecule might be slight, these changes in the manufacturing process of a biosimilar can affect the efficacy and safety of a biosimilar compared to the reference biologic. Over the past decade, the manufacturing process for proteins has become more standardized and the required technology has become increasingly accessible, leading to reductions in biosimilars production costs. As a result, a greater number of companies have begun manufacturing biosimilars, while reference brand manufacturers are setting their sights on bolstering pipelines and manufacturing biobetters to maintain market share for their soon-to-be-off-patent reference products.
BIOSIMILAR DEVELOPMENT NEWS
- Intas Pharmaceuticals And Accord Biopharma Become One Of The Largest Global Suppliers Of Pegfilgrastim With Acquisition Of UDENYCA®
- FDA Approves Expanded Indication For AVTOZMA® (tocilizumab-anoh) intravenous (IV) Formulation In Cytokine Release Syndrome (CRS)
- Polpharma Biologics And Fresenius Kabi Sign Licensing Agreement For Proposed Vedolizumab Biosimilar PB016
- Kashiv BioSciences And MS Pharma Enter Into MENA License And Supply Agreement For ADL-018, Biosimilar Candidate To XOLAIR (bOmalizumab)
- CivicaScript® To Distribute Low-Cost Biosimilar To Treat Chronic Inflammatory Conditions